AMGN CHMP opinion: Thursday, September 17, 2026

Variation type II · Neulasta · Update of sections 4.4, and 4.8 of the SmPC in order to expand an existing warning on aortitis to include medium and large vessel arteritis to further characterize the spectrum of vascular inflammation associated with G-CSF use, and add arteritis to the list of adverse

Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.